Researchers at the Department of Clinical Medicine at Oxford University have developed a new vaccine technology based on a modified adenovirus that can help identify and fight cancer cells and infections.
This latest development works by teaching the immune system how to recognize malignant melanoma, tumor cells or infected cells in malaria and hepatitis, and by producing a large number of "killer T cells" to combat specialized pathological conditions.
The research centered on a type of T cell called CD8 +. Clinical trials have shown that CD8 + plays an important role in combating specific infections and cancer.
Scientists have developed a way to simultaneously use two different structures carrying a specific disease-associated antigen for immunization.
The first structure is an "initial" structure that teaches the immune system to recognize antigens, and the second structure is a "strengthening" structure, based on a modified adenovirus that can no longer cause infection.
Once the body is strengthened by this virus vaccine, the immune system will remember the antigen and prompt the production of a large number of specialized, effective CD8 + killer T cells.
This brings a strengthened immune response to cancer cells or infected cells, which may subdue and block the development of the disease early in the disease.
This vaccine route has been licensed globally and is owned by Oxxon Pharmaccines, a subsidiary company of Oxford University. It is estimated that this adenovirus vaccine will work together with the various guidance reagents currently under development by the company and complement the company's current plans for malignant melanoma and hepatitis B.
Customized Toys,Customized Adhesive Toys,Drip Glue Toys,Cartoon Adhesive Toys
DONGGUAN TETSUMET TECHNOLOGY CO.,LTD , https://www.tetsumet.com